Latest Acquisitions News

Bentley Capital Limited reported a reduced net loss of $878,418 for FY25, driven by unrealised investment losses primarily linked to its significant stake in Strike Resources. The company continues to navigate market volatility and operational hurdles with strategic cost controls and asset sales.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

Steadfast Group Limited reported a robust 47% jump in statutory net profit for FY25, boosted by a significant one-time gain from acquiring Rothbury Group. The company also declared a fully franked final dividend of 11.7 cents per share.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

Foresta Group Holdings reported a $3.375 million net loss for FY2025 while making significant progress on its Kawerau biomass facility in New Zealand, securing key approvals, partnerships, and funding. The company aims to commence construction in FY2026, positioning itself in the renewable energy sector.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit for FY25, marking the completion of its transformative Simply Stronger program that enhanced digital offerings and customer reach.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.